Post-operative pain and lower urinary tract symptoms are common following ureteroscopy in the treatment of stone disease. The use of bupivacaine as a topical pain medication is used routinely for other urologic procedures, however, to date there are no studies that have rigorously investigated the effect of instilling bupivacaine in the bladder following ureteroscopy. This is a randomized study that will investigate the effect of instilling bupivacaine in the bladder following routine ureteroscopy, laser lithotripsy and ureteral stenting in the treatment of stone disease. Compared to a placebo of Normal Saline, our study hypothesizes that administration of topical bupivacaine in the bladder will decrease post-operative pain and lower urinary tract symptoms while improving quality of life in the early post-operative period.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
116
The dose plan is to use 50 ml of 0.25% bupivacaine which corresponds with a total dose of 125mg.
Placebo of 50 ml of Normal Saline
The University of Chicago Medical Center
Chicago, Illinois, United States
RECRUITINGPost-operative pain as determined by the score on a Visual Analog Scale (VAS) upon emergence from anesthesia
Pain will be assessed using a Likert 10-point scale upon emergence from anesthesia in the recovery room, post-emergence 30 minutes, 60 minutes post-emergence and 6 and 24 hours post-emergence. These types of scales are commonly used to measure post operative pain both in anesthesia and in endourology
Time frame: At 30 minutes post-emergence, 60 minutes post-emergence, 6 hours post-emergence and on post-operative day 1
Milliequivalent of morphine consumed
Time frame: From Baseline to post- operative day 5
Number of bladder spasms
Time frame: From Baseline to post- operative day 5
Time to void
Time frame: From Baseline to post- operative day 5
Time to discharge
Time frame: From Baseline to post- operative day 5
Quality of life based on the Ureteral Stent Symptom Questionnaire (USSQ)
A validated tool of 38 questions that assesses the symptoms and quality of life impact of ureteral stents.
Time frame: From Baseline to post- operative day 5
The Patient-Reported Outcomes Measurement Information System (PROMIS) Adult Function Short Form
Time frame: From Baseline to post- operative day 5
Adverse events
Time frame: From Baseline to post- operative day 5
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.